89Zr-labeled NY008 PET Imaging in Patients

Launched by AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY · Dec 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 89Zr-labeled NY008 PET Imaging in patients who have multiple myeloma, a type of blood cancer. The main goal of the trial is to see how safe this imaging method is and how well it distributes in the body. Currently, the trial is looking for participants aged 18 and older who have relapsing or refractory multiple myeloma, meaning their cancer has not responded to previous treatments or has returned after treatment. Participants should also have a heart function that is normal and a good performance status, which means they are generally feeling well enough to participate.

If you or someone you know is considering joining this trial, it’s important to be aware of certain criteria. For instance, individuals with life expectancies of less than three months or those who have had major surgeries recently cannot participate. Additionally, those with serious infections, uncontrolled health conditions, or certain allergies may not be eligible. Participants will undergo PET/CT imaging scans, which are special tests that help doctors see how the treatment is working in the body. Overall, this trial is a step forward in finding better ways to monitor and treat multiple myeloma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Older than 18 years old, male or female;
• • 2. Patients diagnosed with relapsing or refractory multiple myeloma；
• • 3. LVEF≥50%；
• • 4. ECOG score 0\~2；
• Exclusion Criteria:
• • 1. Life expectancy of less than 3 months;
• • 2. Participated in other clinical research within 1 month;
• • 3. Recovery from major trauma (including surgery) within 28 days prior to study treatment;
• • 4. Patients with systemic or locally severe infections, or other serious coexisting diseases;
• • 5. Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines;
• • 6. Patients with autoimmune diseases, including rheumatoid arthritis;
• • 7. Inadequate control of arrhythmias, including atrial fibrillation;
• • 8. Uncontrolled hypertension;
• • 9. Patients with allergies or allergies to any component of the imaging agent or antibody;
• • 10. Patients who cannot undergo PET/CT imaging scan;
• • 11. Syphilis, HBV, HCV, or HIV positive subjects;
• • 12. Male and female subjects of reproductive age cannot take effective contraceptive measures;
• • 13. Pregnant or lactating women;
• • 14. Patients with a history of mental illness or related conditions;
• • 15. Other subjects considered unsuitable by researchers.